ALIVUS

Alivus Life Sciences Share Price

₹1,123.85 -26.05 (-2.27%)

22 Jan, 2025 12:08

SIP TrendupStart SIP in ALIVUS

Start SIP

Performance

  • Low
  • ₹1,111
  • High
  • ₹1,149
  • 52 Week Low
  • ₹677
  • 52 Week High
  • ₹1,335
  • Open Price₹1,130
  • Previous Close₹1,150
  • Volume67,059

Investment Returns

  • Over 1 Month + 10.91%
  • Over 3 Month + 0.98%
  • Over 6 Month + 32.63%
  • Over 1 Year + 40.75%
SIP Lightning

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.5
  • PEG Ratio
  • -2
  • Market Cap Cr
  • 13,770
  • P/B Ratio
  • 5.4
  • Average True Range
  • 48.58
  • EPS
  • 34.56
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.74
  • RSI
  • 68.8
  • MFI
  • 82.91

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,123.85
-26.05 (-2.27%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,050.66
  • 50 Day
  • ₹1,047.89
  • 100 Day
  • ₹1,038.12
  • 200 Day
  • ₹976.89

Resistance and Support

1152.87 Pivot Speed
  • R3 1,329.43
  • R2 1,271.57
  • R1 1,210.73
  • S1 1,092.03
  • S2 1,034.17
  • S3 973.33

What's your outlook on Alivus Life Sciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs), supplying over 130 molecules to more than 700 global pharmaceutical companies. With world-class manufacturing and research capabilities, GLS focuses on operational excellence, regulatory compliance, and innovation.

Alivus Life Sciences Limited has an operating revenue of Rs. 2,204.90 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 28% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 13% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 24 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-23 Quarterly Results
2024-10-24 Quarterly Results
2024-07-25 Quarterly Results
2024-04-25 Audited Results
2024-01-23 Quarterly Results
Date Purpose Remarks
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View More

Alivus Life Sciences F&O

Alivus Life Sciences Shareholding Pattern

75%
3.23%
0.22%
6.74%
10.99%
3.82%

About Alivus Life Sciences

  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Managing Director & CEO
  • Dr. Yasir Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,123 As on 22 January, 2025 | 11:54

The Market Cap of Alivus Life Sciences is ₹13770.4 Cr As on 22 January, 2025 | 11:54

The P/E ratio of Alivus Life Sciences is 32.5 As on 22 January, 2025 | 11:54

The PB ratio of Alivus Life Sciences is 5.4 As on 22 January, 2025 | 11:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23